Annual Clinical and Scientific Conference 2017

June 20-23, 2017 in Ottawa, Ontario

Program is subject to changes.


Prof. Walter Henri Gotlieb MD

Westmount QC
Walter Gotlieb is presently Professor of Ob-Gyn and of Oncology at McGill University. He is the Director of Gynecologic Oncology at the Jewish General Hospital and Director of Surgical Oncology at McGill University. He recently completed an executive course in health care management and delivery at the Harvard Business School. He obtained his medical degree summa cum laude at the Université Libre de Bruxelles, in his native Belgium, where he went on to obtain board certification in Ob-Gyn.

Following two years at the National Institutes of Health, where he obtained the National Cancer Institute Award of Outstanding Performance, he performed a three year fellowship in Gyn-oncology at UCLA. He was then recruited by the by Tel Aviv University, Tel Hashomer Hospital, where he co-founded and built up the Department of Gynecologic-Oncology from 1994 to 2003. In 2003, he was recruited by McGill University.

He obtained license to practice in Europe, Israel, California, and Canada. In addition to his clinical responsibilities, he is involved in scientific research in ovarian cancer as a Project Director in the Lady Davis Research Institute. He has been a pioneer and driven “robotic” surgery in gynaecologic cancer in Canada. He has lectured around the world, and has proctored robotic surgery multiple times in Canada, China, India, and Israel. A recipient of thirteen national and international awards in the area of cancer research, Dr. Gotlieb is well published with over 150 peer-reviewed manuscripts in reputable international journals.

Dr. Gotlieb is President of the Gynecologic Oncology Society of Canada and secretary treasurer of the International Gynecologic Cancer Society. He is senior editor of the International Journal of Gynecologic Cancer. His prior involvements with medical societies include the council of the International Gynecologic Cancer Society, the Israel Gynecologic Oncologists, secretary treasurer of the Society of Gynecologic Oncologists of Canada, the SGO program committee, the International Committee of the SGO, and Vice President of the Association des Gynécologues Oncologues du Québec.


1. I have an affilitation (financial or otherwise) with a pharmaceutical, medical device, or communications organization.

2. I have been a member of AstraZeneca's Advisory Board

3. I have received payment from a commercial organization (including gifts or other consideration or ‘in kind’ compensation) from AstraZeneca.

4. I am currently participating in or have participated in multiple clinical trials within the past 2 years

5. I do not intend to make therapeutic recommendations for medications that have not received regulatory approval (i.e. “off-label” use of medication).